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To the Editor We would like to present a case 
involving a 19‑year‑old man with bone marrow 
suppression and preliminary diagnosis of plas‑
ma cell leukemia after metamizole overuse. Pri‑
or to this diagnosis, our patient was healthy and 
did not use any medication on a regular basis. 
However, he recently suffered from a toothache 
and took from 0.5 to 2 g/d of metamizole for 
3 weeks. After this time, he observed severe sore 
throat, cough, fever, and muscle aches. He con‑
tinued metamizole but this time in combination 
with ibuprofen (400–600 mg/d). A week later, 
the symptoms deteriorated and a general practi‑
tioner prescribed him azithromycin, followed by 
cefuroxime, both without improvement. Final‑
ly, after 5 weeks of overuse of nonsteroidal anti‑ 
‑inflammatory drugs, our patient was admitted 
to the hospital for further diagnostic evaluation 
and treatment.
On admission to the hospital, fever, tachycar‑
dia, palpable and painful peripheral lymph nodes, 
enlarged tonsils with purulent plugs, multiple 
aphthae on the oral mucosa, and dental caries 
were observed. Laboratory tests showed leuco‑
penia (1100/µl) and lymphopenia (900/µl) with 
normal hemoglobin levels and platelet count, and 
high levels of inflammatory markers (C‑reactive 
protein, 255.7 mg/l; procalcitonin, 1.79 ng/ml). 
During hospitalization, red and white blood cell 
counts lowered and were accompanied by liver 
damage and prolonged thrombin and prothrom‑
bin time. Uncommon viral (hepatitis B virus, hep‑
atitis C virus, human immunodeficiency virus, 
cytomegalovirus, Epstein‑Barr virus) and syph‑
ilis infections as well as autoimmune diseases 
were excluded. All microbiological tests, includ‑
ing blood urine and throat swab cultures, were 
negative. Bone marrow aspiration revealed iso‑
lated granulocyte aplasia with plasma cells con‑
stituting 30% of the cells. The patient was trans‑
ferred to the Hematology Unit with suspicion of 
plasma cell leukemia. 
The patient was initially in good condition 
but showed radiologic signs of pneumonia and 
maxillary sinusitis. He was referred to a dentist 
who removed all caries in teeth, but despite us‑
ing wide‑spectrum empiric antibiotics (ceftazi‑
dime, clarithromycin, meropenem, and vanco‑
mycin) his clinical condition worsened and blood 
pancytopenia developed. A bone marrow biopsy 
showed suppression of all lines with 35% of reac‑
tive plasma cells (FIGURE 1A), while in blood smears 
only single plasma cells were present (FIGURE 1B). 
These findings suggested inflammatory or reac‑
tive etiology of the pathology. Active tuberculosis 
of the bone marrow was also excluded but the se‑
rologic blood test showed elevated levels of par‑
vovirus B19‑specific IgM antibodies. We admin‑
istered granulocyte colony‑stimulating factor for 
5 days, but leukopenia persisted. For this reason, 
a second bone marrow biopsy was performed, 
which demonstrated bone marrow regeneration 
but with signs of macrophage activation and he‑
mophagocytosis (FIGURE 1C). This finding was con‑
sistent with the laboratory characteristics of liv‑
er damage and coagulation abnormalities. Macro‑
phage activation syndrome (MAS) was diagnosed 
and corticosteroids were prescribed (dexameth‑
asone 3 × 8 mg/d for 5 days, followed by predni‑
sone 1 mg/kg/d). This resulted in a rapid clinical 
and laboratory improvement. A week later, bone 
marrow aspirate was normal. Systemic steroids 
were tampered for the next 3 weeks and final‑
ly stopped. Four weeks after discharge, the pa‑
tient was healthy, did not take any medications, 
and his laboratory results were normal (includ‑
ing blood cell counts and inflammatory markers).
The most likely cause of bone marrow suppres‑
sion in our patient was the metamizole abuse be‑
cause this medication had been taken for 5 weeks 
(with about 30 g of cumulative dose). Metamizole 
is a commonly used nonsteroidal anti‑inflamma‑
tory drug that is prohibited in many countries due 
to the risk of agranulocytosis. In Poland, it is still 
available without prescription. A national safety 
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survey in Poland showed that the risk of agran‑
ulocytosis was low (0.16 cases per million per‑
son‑days of use).1 In Sweden, its prevalence was 
estimated as 1 per 31,000 patients treated with 
metamizole in the hospital and 1 per 1400 outpa‑
tiens.2 In our patient, the large cumulative dose 
of metamizole might have been critical. We can‑
not also exclude the contribution of parvovirus 
B19 (a common virus transmitted via the respi‑
ratory tract) to bone marrow damage and devel‑
opment of MAS. 
Viral or bacterial respiratory tract infections 
are associated with a wide range of extrapulmo‑
nary manifestations.3 Parvovirus B19 can lead to 
transient aplastic and chronic anemia, depend‑
ing on the host.4 MAS or secondary hemophago‑
cytic lymphohistiocytosis (HLH) is a severe and 
life‑threatening complication observed main‑
ly in patients with autoimmune diseases or vi‑
ral infections.5 The diagnosis is made when 5 of 
8 conditions are fulfilled: 1) fever, 2) splenomega‑
ly, 3) cytopenia in at least 2 cell lines, 4) hypertri‑
glyceridemia and/or hypofibrinogenemia, 5) tis‑
sue presentation of hemophagocytosis, 6) low or 
absent natural killer‑cell activity, 7) serum fer‑
ritin concentration >500 µg/l, and 8) elevated 
levels of soluble CD25 >2 standard deviations 
above the mean (usually >2400 IU/ml). HLH 
treatment depends on the severity and cause of 
the disease, but steroids with or without cyclo‑
sporine are usually required.5
We hope that the presentation of this case will 
help raise awareness of potential harmful side 
effects of metamizole, a widely used nonsteroi‑
dal anti‑inflammatory drug, currently available 
in Poland over the counter.
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FIGURE 1 Bone 
marrow aspirate and 
peripheral blood smears: 
35% infiltration of 
reactive plasma cells in 
the bone marrow (A); 
single plasma cells and 
red cells in the peripheral 
blood (B); activated 
macrophages in the bone 
marrow (C);  
Wright’s stain, 
magnification × 1000
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